Of note, trametinib (a MEK inhibitor approved by the FDA for clinical use) and CC (an AMPK inhibitor) showed a synergistic cytotoxic effect in metabolically stressed cancer cells (Fig. 6f). This evidence concerns the gene MAP2K7 and cancer.